Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study
In conclusion, our results suggest that high sCTLA-4 serum levels might predict favorable clinical outcome and higher risk of irAEs in IPI-treated MM patients.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Immunotherapy | Italy Health | Melanoma | Skin Cancer | Study | Yervoy